Physician profile
Daniel E Panush
NPI 1669457909
$2,621.60
in general payments reported to CMS, 2019-2025
28 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $96.18 · 2021: $495 · 2022: $556 · 2023: $450 · 2024: $449 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.55 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $379.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $208.71 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $185.63 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $176.88 | 2021-2023 | |
| Abbott Laboratories | $94.35 | 2019-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $75.66 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.21 | 2019-2023 | Jardiance |
| Pfizer INC. | $52.88 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $49.48 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $47.31 | 2020-2022 | |
| Glaxosmithkline, LLC. | $45.52 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $43.08 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $43.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.81 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.51 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.49 | 2022-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $24.31 | 2021 | |
| Sanofi Pasteur INC. | $22.31 | 2022 | |
| Pulmonx Corporation | $20.18 | 2022 | |
| Horizon Therapeutics Plc | $16.68 | 2022 | |
| Recor Medical INC | $14.96 | 2025 | Paradise Ultrasound Renal Denervation System |
| Exact Sciences Corporation | $14.31 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $12.90 | 2023 | Onpattro |
| Amarin Pharma, INC. | $12.50 | 2019 | |
| Esperion Therapeutics, INC. | $12.03 | 2022 | |
| Seqirus USA INC | $11.93 | 2022 | |
| Eisai INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Panush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.